1ProLynx LOGO.png
ProLynx announces SBIR grant award to develop long-acting parathyroid hormone for hypo-parathyroidism
07 juil. 2020 09h00 HE | ProLynx LLC
SAN FRANCISCO, July 07, 2020 (GLOBE NEWSWIRE) -- Today ProLynx announced it was awarded a Small Business Innovation Research (SBIR) grant from the NIH. The grant was conferred for the development of...
Ascendis_FINAL_LOGO_7.23.15.png
Ascendis Pharma Expands TransCon™ PTH Phase 2 PaTH Forward Clinical Trial to Expedite Enrollment of Subjects Previously Treated with NATPARA® in the United States
14 nov. 2019 16h01 HE | Ascendis Pharma
- Reflects company values and commitment to patients living with hypoparathyroidism - - Top-line data from expanded PaTH Forward Trial expected in first quarter of 2020 - - Company expects to exceed...
Ascendis_FINAL_LOGO_7.23.15.png
Ascendis Pharma Announces Results of Study at ENDO 2019 Evaluating Impact of Hypoparathyroidism on Patient Quality-of-Life
25 mars 2019 14h00 HE | Ascendis Pharma A/S
COPENHAGEN, Denmark, March 25, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address unmet medical...
Ascendis Pharma A/S Announces Dosing of Subjects in Phase 1 Trial of TransCon PTH
26 sept. 2017 08h00 HE | Ascendis Pharma A/S
COPENHAGEN, Denmark, Sept. 26, 2017 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet...